GlassScriptPhysician profile
Adour Adrouny
NPI 1447298955
$1,819.33
in general payments reported to CMS, 2019-2025
16 companies · $458 in 2025
The $458 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $55.37 · 2022: $63.44 · 2023: $457 · 2024: $786 · 2025: $458.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,691 · Education: $9.09.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,691.43 |
| Education | $9.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $266.18 | 2024 | Calquence, Enhertu |
| E.R. Squibb & Sons, L.L.C. | $243.31 | 2021-2024 | Opdivo, Reblozyl, Augtyro |
| Abbvie INC. | $218.28 | 2023-2025 | Venclexta |
| Daiichi Sankyo INC. | $207.09 | 2024-2025 | Injectafer |
| Janssen Biotech, INC. | $136.93 | 2024 | Darzalex, Tecvayli |
| Pfizer INC. | $134.60 | 2021-2025 | |
| Amgen INC. | $127.46 | 2023-2024 | Kyprolis, Lumakras, Nplate |
| Adaptive Biotechnologies Corporation | $126.10 | 2025 | Clonoseq |
| Seagen INC. | $104.74 | 2023 | Adcetris |
| Merck Sharp & Dohme LLC | $71.13 | 2023 | Keytruda |
| Eisai INC. | $63.06 | 2024 | |
| Karyopharm Therapeutics INC. | $45.97 | 2023 | Xpovio |
| Lilly USA, LLC | $24.34 | 2023 | Cyramza |
| Celgene Corporation | $21.51 | 2023 | Reblozyl |
| Alnylam Pharmaceuticals INC. | $14.60 | 2023 | Oxlumo |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stemline Therapeutics INC. | $14.03 | 2023 | Orserdu |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adour Adrouny listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.